Affinity Asset Advisors, LLC Esperion Therapeutics, Inc. Transaction History
Affinity Asset Advisors, LLC
- $560 Million
- Q4 2024
A detailed history of Affinity Asset Advisors, LLC transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Affinity Asset Advisors, LLC holds 350,000 shares of ESPR stock, worth $637,000. This represents 0.2% of its overall portfolio holdings.
Number of Shares
350,000Holding current value
$637,000% of portfolio
0.2%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding ESPR
# of Institutions
215Shares Held
129MCall Options Held
1.78MPut Options Held
1.27M-
Wasatch Advisors Inc Salt Lake City, UT24.5MShares$44.6 Million0.27% of portfolio
-
Black Rock Inc. New York, NY14MShares$25.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$21.3 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.94MShares$18.1 Million0.44% of portfolio
-
Morgan Stanley New York, NY6.31MShares$11.5 Million0.0% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $121M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...